ITALIANO, A.; BELLERA, Carine; D'ANGELO, S.

doi:10.1186/s13045-020-00891-5

BELLERA, Carine
Bordeaux population health [BPH]

D'ANGELO, S.

Langue

Article de revue

Ce document a été publié dans

Journal of Hematology and Oncology. 2020, vol. 13, n° 1, p. 55

Résumé en anglais

Immune checkpoint inhibitors, especially the programmed cell death receptor-1/ligand 1 (PD-1/L1) inhibitors, displayed promising efficacy in several solid tumor types and hematological malignancies. Data related to their activity in soft-tissue sarcomas (STS) are scarce.We performed a pooled analysis of clinical trials investigating a PD1 or PD-L1 antagonist in patients with advanced STS. Three hundred eighty-four patients were included in the pooled analysis; of those, 153 (39.8%) received a PD1/PD-L1 antagonist as a single agent. In patients treated with anti-PD1/PDL1 as a single agent, the overall response rate (ORR) and non-progression rate (NPR) were 15.1% and 58.5% respectively. In patients treated with a combination regimen, the ORR and NPR were 13.4% and 55.8% respectively. Analysis by histological subtype revealed that patients with alveolar soft part sarcoma and undifferentiated pleomorphic sarcoma exhibited the highest response rates and leiomyosarcoma the lowest. PD-L1 expression rate was low and inconsistently associated with objective response.PD-1/PD-L1 antagonists have limited activity in unselected STS. Future studies should implement histology and immune-based stratification of STS in their design as well as sequential blood and tissue sampling to better understand the mechanisms of resistance and response given sarcomas inherent heterogeneity.< Réduire

Mots clés

EPICENE

URI

https://oskar-bordeaux.fr/handle/20.500.12278/26043

DOI

http://dx.doi.org/10.1186/s13045-020-00891-5

Unités de recherche

Bordeaux Population Health Research Center (BPH) - UMR 1219

Voir/Ouvrir

Métadonnées

Partager cette publication !

Licence d’utilisation du document

PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés

URI

DOI

Unités de recherche